Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 4, pp 124–127 | Cite as

Fluoroquinolones

Adverse reactions during clinical trials and postmarketing surveillance
  • R. Janknegt
Therapeutic Interventions in Lower Respiratory Tract Infections

Abstract

The knowledge of side effects of fluoroquinolones during clinical trials and postmarketing surveillance is reviewed. Gastro-intestinal side effects (observed in 3–6% of the patients) are the most frequently observed side effects followed by side effects of the central nervous system (0.5–1.5%) and skin reactions (0.5–2%). The incidence of severe side effects is very low and most effects can be reserved rapidly upon discontinuation of therapy. Reactions of the central nervous system (sometimes severe) were the most often spontaneously reported events during the postmarketing surveillance of ofloxacin. The incidence of adverse reactions is usually in the same range as that of other antimicrobial agents like the third generation cephalosporins, imipenem and aztreonam. Fluoroquinolones are usually well-tolerated and safe drugs, but more data is needed on the long-term safety of quinolones, the safety in children, in elderly people and in severely ill patients.

Keywords

Clinical trials Fluoroquinolones Product surveillance, postmarketing Side effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis 1988;10S1:S258–62.Google Scholar
  2. 2.
    Fass RJ. Adverse reactions associated with quinolones. Quinol Bull 1987;3:5–6.Google Scholar
  3. 3.
    Janknegt R, Nix DE, Schentag JJ. Side effects. In: Quinolones basic facts and clinical experience. Hekster YA, Bergan T, Adam D, eds. New York: Marcel Dekker (in press).Google Scholar
  4. 4.
    Saito A. Side effects of new quinolones. 15th International congress on chemotherapy. Istanbul, 1987: abstract 1449.Google Scholar
  5. 5.
    Jüngst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987;34S2:144–9.Google Scholar
  6. 6.
    Corrado ML, Strubble WE, Peter C, Hoogland V, Sabbaj J. Norfloxacin: Review of safety studies. Am J Med 1987;82(Suppl B):22–6.PubMedGoogle Scholar
  7. 7.
    Schnuch A. Gyrase-Hemmer: zentral nervöse Nebenwirkungen. Dtsch Med Wochenschr 1987;112:569.Google Scholar
  8. 8.
    Hori S, Shimada J, Saito A, et al. Effect of new quinolones on γ-aminobutyric acid receptor binding. 25th Interscience conference on antimicrobial agents and chemotherapy. Minneapolis, 1985. Washington: American Society for Microbiology, 1985:abstract 396.Google Scholar
  9. 9.
    Smith CR. The adverse effects of fluoroquinolones. J Antimicrob Chemother 1987;19:709–11.PubMedGoogle Scholar
  10. 10.
    Rietbrock N, Staib AH. Gyrase-hemmer: unerwünschte zentralnervöse Wirkungen. Dtsch Med Wochenschr 1987;112:201.PubMedGoogle Scholar
  11. 11.
    Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R. Crystalluria and ciprofloxacin, influence of urinary pH and hydratation. Chemotherapy 1986;32:408–17.PubMedGoogle Scholar
  12. 12.
    Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983;23:284–8.PubMedGoogle Scholar
  13. 13.
    Falkenberg FW, Mondorf AW, Dalhoff A. Untersuchungen über die NierenvertrÄglichkeit von Ciprofloxacin mit Hilfe monoklonaler Antikörper. FAC 1987;6–10:2265–80.Google Scholar
  14. 14.
    Chamouard P, Duclos B, Welsch M, Gold A. Thrombopénie sévère et réversible induite par la norfloxacine. Presse Med 1987;16:1978–9.Google Scholar
  15. 15.
    Patoia L, Guerciolini R, Menichetti F, Bucaneve G, Del Favero A. Norfloxacin and neutropenia. Ann Intern Med 1987;107:788–9.Google Scholar
  16. 16.
    Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol 1988;26:1–5.PubMedGoogle Scholar
  17. 17.
    Rawlins MD. Spontaneous reporting of adverse drug reactions. II: uses. Br J Clin Pharmacol 1988;26:7–11.PubMedGoogle Scholar
  18. 18.
    Jüngst G, Mohr R. Overview of postmarketing ADR experience with ofloxacin in Germany. 2nd International symposium on new quinolones. Geneva, 1988: posterno. 188.Google Scholar
  19. 19.
    Jüngst G, Mohr R. Overview of postmarketing experience with ofloxacin in Germany. J Antimicrob Chemother 1988;22C;167–75.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • R. Janknegt
    • 1
  1. 1.Department of Clinical Pharmacy and ToxicologyMaasland Hospital Sittard/GeleenMB Sittardthe Netherlands

Personalised recommendations